AstraZeneca Pharma shares fall over 6% after Q4 results; Margins and profitability under pressure

Shares of AstraZeneca Pharma India fell more than 6% in Wednesday’s trading session after the company reported weak profitability numbers for the quarter ended March 2026, despite posting healthy revenue growth.

At around 10:54 AM IST, AstraZeneca Pharma shares were trading sharply lower as investors reacted to declining margins and lower quarterly earnings.

The stock opened at Rs 8,826.00 against the previous close of Rs 8,962.50. During the session, it touched an intraday high of Rs 8,826.00 and slipped to a low of Rs 8,378.00. The stock has a 52-week high of Rs 10,691.00 and a 52-week low of Rs 7,551.50. Live trading volume stood at 23,275 shares.

For the fourth quarter of FY26, AstraZeneca Pharma reported revenue of Rs 579 crore, up 20.4% year-on-year compared to Rs 481 crore in the corresponding quarter last year. The strong top-line growth indicates steady demand momentum across its pharmaceutical portfolio.

However, operational performance remained under pressure during the quarter. EBITDA declined 29.5% to Rs 60.9 crore from Rs 86.4 crore reported in the same period last year. EBITDA margins also contracted significantly to 10.5% from 18.0%, reflecting rising cost pressures and weaker operational efficiency.

The company’s bottom line also weakened during the quarter. Net profit fell 23.0% year-on-year to Rs 44.9 crore compared to Rs 58.3 crore in the year-ago period.

The sharp correction in the stock price suggests that investors were concerned about margin compression and declining profitability despite healthy revenue expansion. Market participants will continue to monitor whether the company can improve operational efficiency and restore earnings momentum in the coming quarters.

AstraZeneca Pharma remains one of the key players in India’s pharmaceutical sector, focusing on therapies across oncology, cardiovascular, respiratory, and rare diseases segments.

Disclaimer: This article is for informational purposes only and should not be construed as investment advice. Stock market investments are subject to market risks. Readers are advised to consult their financial advisor before making any investment decisions. The views and market data mentioned are based on publicly available information and are subject to change. Past performance is not indicative of future returns. Neither the author nor the publisher is responsible for any losses arising from investment decisions based on this article.